Joseph E Tota

List of Publications by Year
in descending order

36	1,144	566801 15	395343 33
papers	citations	h-index	g-index

37	37	37	1868
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of a Carrageenan Gel in Increasing Clearance of Anal Human Papillomavirus Infections in Men: Interim Analysis of a Double-Blind, Randomized Controlled Trial. Journal of Infectious Diseases, 2023, 227, 402-406.	1.9	1
2	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. Journal of Infectious Diseases, 2021, 223, 1576-1581.	1.9	7
3	Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. Sexually Transmitted Infections, 2021, , sextrans-2021-055009.	0.8	2
4	Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial. Contemporary Clinical Trials, 2021, 110, 106560.	0.8	3
5	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. Journal of the National Cancer Institute, 2020, 112, 818-828.	3.0	19
6	Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial. BMJ Open, 2020, 10, e035113.	0.8	5
7	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. Oral Oncology, 2020, 108, 104736.	0.8	40
8	Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening. International Journal of Cancer, 2020, 147, 3305-3312.	2.3	12
9	Identification of HPV genotypes causing cervical precancer using tissueâ€based genotyping. International Journal of Cancer, 2020, 146, 2836-2844.	2.3	13
10	Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. Cancer, 2019, 125, 4407-4416.	2.0	19
11	Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. Journal of Clinical Oncology, 2019, 37, 1538-1546.	0.8	127
12	Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virusâ€infected individuals in the United States. Cancer, 2018, 124, 2515-2522.	2.0	12
13	Journal editors as curators of scholarship: A case study in repairing the scientific record. Preventive Medicine, 2018, 110, 114-115.	1.6	2
14	Rising incidence of oral tongue cancer among white men and women in the United States, 1973â€“2012. Oral Oncology, 2017, 67, 146-152.	0.8	124
15	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	1.6	87
16	Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecologic Oncology, 2017, 144, 391-395.	0.6	10
17	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute, 2017, 109, djw300.	3.0	43
18	Population health intervention research: A renewed commitment to promoting a science of solutions. Preventive Medicine, 2017, 100, 1-2.	1.6	2

#	Article	IF	Citations
19	Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. Preventive Medicine, 2017, 98, 15-20.	1.6	34
20	Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections. Journal of Infectious Diseases, 2016, 214, 676-684.	1.9	9
21	Should we lower the age for routine HPV vaccination in the United States?. Preventive Medicine, 2016, 89, 334-336.	1.6	0
22	Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. PLoS ONE, 2016, 11, e0166329.	1.1	17
23	Sobering realizations in cancer prevention and screening and their lessons. Preventive Medicine, 2015, 76, 129-131.	1.6	1
24	An elusive low-hanging fruit for public health: Gun violence prevention. Preventive Medicine, 2015, 79, 1-2.	1.6	8
25	Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 286-290.	1.1	24
26	Guillainâ€“Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Human Vaccines and Immunotherapeutics, 2014, 10, 232-237.	1.4	26
27	Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios. Lung, 2014, 192, 55-63.	1.4	36
28	Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers. Gynecologic Oncology, 2014, 134, 309-313.	0.6	9
29	Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination. American Journal of Epidemiology, 2013, 178, 625-634.	1.6	87
30	Cervical human papillomavirus detection is not affected by menstrual phase. Sexually Transmitted Infections, 2013, 89, 202-206.	0.8	4
31	Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine, 2011, 53, S12-S21.	1.6	201
32	Optimizing technology for cervical cancer screening in high-resource settings. Expert Review of Obstetrics and Gynecology, 2011, 6, 343-353.	0.4	18
33	The association between having a household member with a cancer-related limitation and human papillomavirus vaccine uptake. Nature Precedings, 2010, , .	0.1	0
34	Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sexual Health, 2010, 7, 376.	0.4	29
35	Effectiveness of Cervical Cancer Screening at Different Ages. Women's Health, 2009, 5, 613-616.	0.7	4
36	The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change. Archives of Medical Research, 2009, 40, 478-485.	1.5	104